Skip To Main Content
Davide Barbisan on Muck Rack

Davide Barbisan

As seen in: Wiley Online Library, Medscape, jhltonline.org
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Davide

Contact Davide, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Dynamic evolution of tricuspid regurgitation during hospitalization in patients with acute decompensated heart failure

|
By Davide Barbisan, Eugenio Zocca, Daniele Cocianni, Maria Perotto
| Wiley Online Library Verified
Supporting Information Filename Description ejhf3433-sup-0001-supinfo.docxWord 2007 document , 2.1 MB Appendix S1. Supporting Information. References 1, , , , , , et al.; EuroHeart Survey Investigators. EuroHeart Failure Survey II (EHFS II): A survey on hospitalized acute heart failure patients: Description of population. Eur Heart J 2006; 27: 2725–2736. https://doi.org/10.1093/eurheartj/ehl193 2. Tricuspid regurgitation. N Engl J Med 2023; 388: 1876–1891.
Open in Who Shared Issue with article?

Phenotype and outcomes according to loop diuretic use in pulmonary arterial hypertension

|
By Davide Barbisan, Pietro Ameri, Carlo Lombardi, Giulio Savonitto
| Wiley Online Library Verified
Introduction Pulmonary arterial hypertension (PAH) is a rare disease characterized by an unfavourable remodelling of the pulmonary vessels, leading to ventricular-arterial uncoupling and, finally, right ventricle (RV) failure.
Open in Who Shared Issue with article?

Performance of risk stratification scores and role of comorbidities in older vs younger patients with pulmonary arterial hypertension

|
By Davide Stolfo, Davide Barbisan, Pietro Ameri
| jhltonline.org Verified
Risk scores are important tools for the prognostic stratification of pulmonary arterial hypertension (PAH). Their performance and the additional impact of comorbidities across age groups is unknown. Patients with PAH enrolled from 2001 to 2021 were divided in ≥65 years old vs <65 years old patients. Study outcome was 5-year all-cause mortality. FPHN, FPHN non-invasive, COMPERA and REVEAL 2.0 risk scores were calculated and patients categorized at low, intermediate and high risk.
Open in Who Shared Issue with article?
See all 4 articles